Wall Street analysts rush to Eli Lilly's defense but investors aren't listening yet

U.S. equities closed higher Friday, with the Nasdaq poised for a record, as attention shifts to next week's crucial CPI data for Federal Reserve policy cues. Eli Lilly shares extended Thursday's 14% decline, falling an additional 2.5% despite Wall Street analysts' defense against the sell-off following disappointing obesity drug trial results, prompting Jim Cramer's Club to downgrade the stock to "sell into strength." Concurrently, Meta Platforms secured a $29 billion financing deal led by Blue Owl Capital and PIMCO to fund its data center expansion, underscoring its significant investment in AI.

Analysis

U.S. equity markets demonstrated strength, with the S&P 500 and Dow advancing and the Nasdaq targeting a new record high, though investor focus is shifting towards next week's Consumer Price Index (CPI) data, which holds significant implications for the Federal Reserve's anticipated September rate decision. In company-specific news, Eli Lilly (LLY) experienced a significant divergence between analyst opinion and investor sentiment. Following a 14% drop on Thursday due to disappointing trial data for its oral obesity drug, the stock fell an additional 2.5% on Friday. This occurred despite bullish commentary from Morgan Stanley, which termed the sell-off "overdone," and JPMorgan, which identified a "compelling entry point." Reflecting investor hesitation, Jim Cramer's Club downgraded LLY to a "sell into strength" rating and cut its price target to $800 from $1,000. Conversely, Meta Platforms (META) signaled a strong commitment to its artificial intelligence ambitions by reportedly securing a $29 billion financing deal with Blue Owl Capital and PIMCO to fund data center expansion, a move that was met with market approval and a slight uptick in its share price.

Key Decisions for Investors

• Investors should exercise caution ahead of the upcoming CPI release, as an unexpectedly high inflation reading could force a repricing of Fed rate cut expectations and disrupt the current market rally.
• For Eli Lilly, the stark contrast between bullish analyst ratings and sustained negative price momentum suggests it may be prudent to wait for investor sentiment to stabilize before considering new positions, as near-term rallies could present selling opportunities.
• Meta's $29 billion financing for AI infrastructure reinforces its long-term strategic focus, and investors may view this aggressive capital allocation as a positive indicator of the company's commitment to a key growth sector.